文献速递细菌感染、耐药与抗菌药物

携带blaCTX-M-55和rmtB的大肠埃希菌临床分离株中blaNDM-21——blaNDM的新变体

blaNDM-21, a new variant of blaNDM in an Escherichia coli clinical isolate carrying blaCTX-M-55 and rmtB.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

对一株耐碳青霉烯类大肠埃希菌进行全基因组测序,鉴定出NDM新变体NDM-21,其与NDM-5仅差第69位甘氨酸至丝氨酸替换(G69S),对碳青霉烯类活性与NDM-5相同。blaNDM-21位于46.1 kb IncX3自传递质粒,遗传背景与blaNDM-5相同,该菌株另携blaCTX-M-55和rmtB。

要点

  • NDM-21与NDM-5仅差G69S替换,对碳青霉烯类活性与NDM-5相同。
  • blaNDM-21位于46.1 kb IncX3自传递质粒,遗传背景与blaNDM-5相同。
  • 该菌株另携blaCTX-M-55(产ESBL,介导氨曲南耐药)和rmtB(介导氨基糖苷类高水平耐药)。

核心结论

  • 鉴定出NDM新变体NDM-21,blaNDM-21在IncX3质粒上由blaNDM-5进化而来。

研究设计与样本

  • 对一株耐碳青霉烯类大肠埃希菌行Illumina X10全基因组测序以鉴定耐药基因和ST。
  • 将新blaNDM基因克隆入大肠埃希菌DH5α,以blaNDM-5为对照,转化子行碳青霉烯类药敏试验。
  • 通过接合转移获得携带新blaNDM基因的质粒,并用MinION长读长测序获得完整质粒序列。

主要发现

  • 该大肠埃希菌分离株属ST617和系统发育群A,携带编码NDM-21的新NDM变体基因。
  • NDM-21与NDM-5仅差第69位甘氨酸至丝氨酸替换(G69S),对碳青霉烯类活性与NDM-5相同。
  • blaNDM-21位于46.1 kb IncX3自传递质粒,遗传背景与blaNDM-5相同。
  • 该菌株另在IncFII质粒上携blaCTX-M-55(产ESBL,介导氨曲南耐药,使其对全部临床可用β-内酰胺类耐药)和rmtB(介导氨基糖苷类高水平耐药)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: New Delhi MBL (NDM) is a type of carbapenemase; 20 variants of NDM have been identified to date. We have found a new variant of NDM, NDM-21, and describe it here. METHODS: A carbapenem-resistant Escherichia coli was subjected to WGS using an Illumina X10 sequencer to identify the antimicrobial resistance genes and its ST. The gene encoding the new variant of NDM was cloned into E. coli DH5α, with blaNDM-5 being cloned as the control. Transformants were tested for susceptibility to carbapenems. Mating was performed to obtain the plasmid carrying the new blaNDM gene and the complete plasmid sequence was obtained using long-read MinION sequencing. RESULTS: The E. coli isolate belonged to ST617 and phylogenetic group A. It had a gene encoding NDM-21, a new NDM variant. NDM-21 differs from NDM-5 by a Gly-to-Ser amino acid substitution at position 69 (G69S). NDM-21 retains the same activity against carbapenems as NDM-5. blaNDM-21 is carried by a 46.1 kb IncX3 plasmid, which is self-transmissible, and is located in a complex genetic context as blaNDM-5. The isolate also carried blaCTX-M-55, which encodes an ESBL conferring resistance to aztreonam (which completed its resistance to all clinically available β-lactams), and rmtB, which mediates high-level resistance to aminoglycosides, on an IncFII plasmid. CONCLUSIONS: A new NDM variant has been identified and blaNDM-21 has evolved from blaNDM-5 on an IncX3 plasmid.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Liu L, Feng Y, McNally A, et al. blaNDM-21, a new variant of blaNDM in an Escherichia coli clinical isolate carrying blaCTX-M-55 and rmtB. J Antimicrob Chemother. 2018. PMID: 29912337. doi:10.1093/jac/dky226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。